Health Canada has approved AstraZeneca's (NYSE: AZN) (LSE: AZN) Imfinzi (durvalumab) for the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT), the company's Canadian unit said on Tuesday.
With this approval, Imfinzi is the first and only approved immuno-oncology therapy following CRT for patients in this setting.
Health Canada's decision was based on data from the phase III PACIFIC trial which demonstrated that Imfinzi extended progression-free survival for patients by nearly one year (11.2 months) versus placebo. This represents a 48% reduction in relative risk of progression or death versus placebo in all patients, regardless of programmed death-ligand 1 (PD-L1) status.
Around 35% of all new NSCLC diagnoses are stage III, and approximately 80% of these patients are unsuitable for surgery.
IDEAYA Biosciences submits IND for IDE892; Targets Phase 1 in 4Q 2025
Airiver medical receives FDA approval for central airway stenosis trial
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Innovent Biologics receives approval over squamous cell lung cancer study
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China